Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposome Bupivacaine Block for Chronic Pain After Breast Cancer Surgery
NCT06427044Not yet recruiting
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bupivacaine in chronic postsurgical pain (CPSP) (2 arms). Primary endpoint: Incidence of chronic pain 3 months after surgery. Planned start May 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
chronic postsurgical pain (CPSP)
Beyond the preview
Go deeper on NCT06427044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427044.